510(k) · Cleared
ClearedBD Phoenix Automated Microbiology System - Erythromycin-0.0625-8 UG/ML, and Quinupristin/Dalfopristin-0.25-4 UG/ML
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Becton, Dickinson & CO · LON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation
Cleared on Mar 17, 2006 as substantially equivalent to K020321 (Becton, Dickinson & CO, 2002) and 3 other predicates after a 49-day review. Its family tree reaches back 2 generations to 2002.
- Decided
- Mar 17, 2006
- Review
- 49 days
- Class
- Class II
- Product code
- LON
- Recalls
- None
- Predicates
- 5
Its longest line of descent runs back 2 generations to K020322 (2002). 6 ancestors in all. No later device cites it as a predicate yet.
- Root · 2 generations backK020322 BD Phoenix Automated Microbiology SystemBecton, Dickinson & CO · 2002
- 1 generation backK022172 BD Phoenix Automated Microbiology SystemBecton, Dickinson & CO · 2002
- This deviceK060218 BD Phoenix Automated Microbiology System - Erythromycin-0.0625-8…Becton, Dickinson & CO · 2006
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K020322 | BD Phoenix Automated Microbiology System | Becton, Dickinson & CO | 2002 | — |
| −1 | K022172 | BD Phoenix Automated Microbiology System | Becton, Dickinson & CO | 2002 | — |
| 0 (this device) | K060218 | BD Phoenix Automated Microbiology System - Erythromycin-0.0625-8 UG/ML, and… | Becton, Dickinson & CO | 2006 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2002 | 2 | 0 |
| 2004 | 2 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in LON? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new LON device
- #1 K260619 VITEK 2 AST-Streptococcus Cefepime (<=0.06 –…score 13.3 · 5 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (5)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary; numbers the summary cites that cannot be its predicate are marked – and kept off the family tree.
| Type | Number | Device | Decided |
|---|---|---|---|
| Kept off the family tree | N50510 | FDA’s N50510 is Vitek Systems General Susceptibility Card Number could not be read Summary page 1…ntimicrobial Susceptibility Device, 21 CFR 866.1645 PREDICATE DEVICES: VITEK® System (PMA No. N505 10) and BD Phoenix TM Automated Microbiology System with Gatifloxacin (K020321,… | 1978 |
| * | K020321 | BD Phoenix Automated Microbiology SystemSummary page 1…VITEK® System (PMA No. N505 10) and BD Phoenix TM Automated Microbiology System with Gatifloxacin (K020321, May 23, 2002, Erythromycin (K033784, February 3, 2004),… | 2002 |
| * | K033784 | BD Phoenix Automated Microbiology System - Erythromycin 0.0625-8 UG/MLSummary page 1…Automated Microbiology System with Gatifloxacin (K020321, May 23, 2002, Erythromycin (K033784, February 3, 2004), Quinupristin/dalfopristin (K022172, August 12, 2002), and… | 2004 |
| * | K022172 | BD Phoenix Automated Microbiology SystemSummary page 1…May 23, 2002, Erythromycin (K033784, February 3, 2004), Quinupristin/dalfopristin (K022172, August 12, 2002), and Chloramphenicol (K033889, February 3, 2004). INTENDED USE:… | 2002 |
| * | K033889 | BD Phoenix Automated Microbiology System for Use with the Antimicrobial Agent…Summary page 1…Quinupristin/dalfopristin (K022172, August 12, 2002), and Chloramphenicol (K033889, February 3, 2004). INTENDED USE: The BD Phoenix M T… | 2004 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 4 years and passes through 1 company; a new generation was cleared every 3.6 years on median.
- 1 of the 6 ancestors has a recall of any class.
- 102 other devices also cite its predicate K020321.
How does its category compare?
All LON devicesLON System, Test, Automated, Antimicrobial Susceptibility, Short Incubation: FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · LON
5in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · LON
90in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · LON
1in 2025
Class I (2 since 2007) Class II/III not classified
Adverse event reports per year · LON
690in 2025
MAUDE reports naming product code LON, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 19 | 50 | 0 | 3 |
| 2008 | 7 | 66 | 1 | 1 |
| 2009 | 8 | 76 | 0 | 0 |
| 2010 | 1 | — | 116 | 3 |
| 2011 | 8 | 85 | 3 | 4 |
| 2012 | 10 | 200 | 3 | 9 |
| 2013 | 7 | 115 | 0 | 3 |
| 2014 | 4 | 90 | 2 (2) | 10 |
| 2015 | 0 | — | 0 | 41 |
| 2016 | 3 | 242 | 2 | 94 |
| 2017 | 10 | 89 | 1 | 197 |
| 2018 | 4 | 88 | 6 | 512 |
| 2019 | 8 | 84 | 1 | 315 |
| 2020 | 5 | 81 | 8 | 218 |
| 2021 | 5 | 268 | 0 | 232 |
| 2022 | 8 | 189 | 15 | 180 |
| 2023 | 11 | 210 | 0 | 453 |
| 2024 | 2 | — | 1 | 418 |
| 2025 | 5 | 90 | 1 | 690 |
| 2026 | 4 | 146 | 6 | — |
What is it indicated for?
The BD PhoenixTM Automated Microbiology System is intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus. This…
Read the full statement (249 words)
The BD PhoenixTM Automated Microbiology System is intended for in vitro quantitative
determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most
Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture for
Enterobacteriaceae and Non-Enterobacteriaceae and most Gram-positive bacteria isolates from pure
culture belonging to the genera Staphylococcus, Enterococcus, and Streptococcus.
This premarket notification is for additional organism groups and BD Phoenix TM Automated Microbiology System with erythromycin (0.0625-8 pg/mL), quinupristin/dalfopristin (0.25-4
gg/mL), and chloramphenicol (1-32 pg/mL) on ID/AST or AST only Phoenix panels.
Erythromycin has been shown to be active in vitro against most strains of microorganisms listed
below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Staphylococcus aureus
Quinupristin/dalfopristin has been shown to be active in vitro against most strains of microorganisms
listed below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Aerobic Gram-positive microorganisms
Enterococcus faecium (vancomycin-resistant and multi-drug resistant strains only)
Staphylococcus aureus (methicillin-susceptible strains only)
Active In Vitro Against:
Aerobic Gram-positive microorganisms
Staphylococcus aureus (methicillin-resistant strains)
Staphylococcus epidermidis (including methicillin-resistant strains)
Synercid is not active against Enterococcus faecalis. Differentiation of enterococcal species is
important to avoid misidentification of Enterococcus faecalis as Enterococcus faecium.
Chloramphenicol has been shown to be active in vitro against most strains of microorganisms listed
below, as described in the FDA-approved package insert for this antimicrobial agent.
Active In Vitro and in Clinical Infections Against:
Staphylococcus aureus
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K060218 · printed Nov 5, 2026
Cite this page
510(k) Report. “K060218: BD Phoenix Automated Microbiology System - Erythromycin-0.0625-8 UG/ML, and Quinupristin/Dalfopristin-0.25-4 UG/ML.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 5, 2026. https://510kreport.com/device/K060218
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026